Connect your AI

Cytek Biosciences, Inc. CTKB Thereafter

Other financials

Income statement

Revenue$44.1M+6.5%

Gross profit$21.3M+5.4%

Operating income-$18.5M-23.3%

Net income-$18.9M-65.5%

EPS (diluted)-$0.15-66.7%

Balance sheet

Cash & equivalents$31.8M-66.6%

Total debt$16.8M+40.9%

Total equity$327.6M-13.7%

Total assets$449.1M-6.9%

Cash flow

Operating cash flow-$2.7M-2,089%

CapEx$2.2M+155%

Free cash flow-$4.9M-403%

Valuation

Market cap$577.27M+54.5%

Enterprise value$562.23M+93.7%

P/S2.8×+0.9×

Profitability

Gross margin51.7%-3.2pp

Operating margin-21.5%—

Net margin-36.2%—

FCF margin-6.2%-15.1pp

Returns & leverage

Return on equity-20.9%—

Debt / equity0.1×0.0×

Current ratio4.7×-0.9×

Where this comes from

Reported directly by Cytek Biosciences, Inc. in its filing.

Tagged under the XBRL concept ctkb:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour.

The official record: Cytek Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cytek Biosciences, Inc.'s thereafter.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Cytek Biosciences, Inc.'s thereafter?: Cytek Biosciences, Inc. (CTKB) reported thereafter of $7.14M in Q1 2026.